A Phase 3 interventional study of Xanomeline/trospium in Schizophrenia; Psychosis and Cognitive Impairment, sponsored by European Group for Research In Schizophrenia. Withdrawn at 16 sites in 10 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by European Group for Research In Schizophrenia · Phase 3, Interventional, and Treatment
Ethical committee in Europe did not provide approval
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.
Among the 20 studies testing xanomeline in Schizophrenia, this one is the 20th largest by enrollment, is the only one that started in 2027, is one of 14 in phase 3, and was the 15th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States, Argentina, Bulgaria and 4 more countries
Ages 18–65
New York State Psychiatric Institute · Sites in United States
Ages 18–50
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States, Australia, Canada and 8 more countries
Ages 5–17
Bristol-Myers Squibb · Sites in United States, Colombia, Japan and 1 more country
Ages 13–17
Bristol-Myers Squibb · Sites in United States
Ages 18–65
By country, each count listing its studies:
xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 14 · Phase 4 3
First in 2018; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 178 across the 20 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 20 have an industry lead sponsor. The 7 most frequent:
This is the only study on the registry with European Group for Research In Schizophrenia as lead sponsor.
European Group for Research In Schizophrenia has 1 study filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
2 of the studies testing xanomeline in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07423546New York State Psychiatric InstituteA PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia | 2027-04-30 |
| NCT07061288Bristol-Myers SquibbA Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT | 2027-06-21 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing xanomeline in Schizophrenia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Schizophrenia is a long-lasting and serious mental health disorder that affects about 1% of people worldwide. It can cause symptoms such as hallucinations and delusions (called positive symptoms), confused or disorganized thinking, reduced motivation and emotional expression (negative symptoms), difficulties with memory and concentration (cognitive symptoms), and movement problems like restlessness or slowed activity. Current treatments, called antipsychotics, mainly work by blocking dopamine in the brain. These medicines are helpful for hallucinations and delusions, but they do little to improve negative or cognitive symptoms.
A new medicine, Xanomeline/Trospium (XT), works differently. It targets a brain system called the muscarinic acetylcholine receptors while limiting side effects elsewhere in the body. Clinical trials have shown that XT reduces psychotic symptoms effectively and is generally well tolerated. The FDA approved XT in 2024 for adults with schizophrenia. Importantly, early results also suggest that XT may help improve thinking and memory (cognition domains), though this has not yet been studied in depth.
Most schizophrenia drug studies pay little attention to long-term changes in cognition, often using only short screening tests. This study will be the first to take a deep look at cognitive function over a full year of XT treatment. It will also examine how changes in thinking skills connect with other aspects of life, such as symptom control, daily functioning, and quality of life. By making cognition a central outcome, the study responds to an urgent need in schizophrenia research: moving beyond just controlling hallucinations and delusions toward improving real-world recovery. The results could help shape future treatment strategies and support the idea that cognition should be a core treatment target in schizophrenia.
This is a phase III, prospective, open-label, single-arm, international, multicenter study. At visit 1, the informed consent is signed and screening is performed to confirm eligibility. At visit 2, baseline measures are performed, and the new treatment is initiated. Max. 14 days after the baseline visit, the pre-study antipsychotic treatment is withdrawn via tapering. At visit 3, 4, 5, 7 and 9 participants' general wellbeing and safety is assessed. At visit 6, 8 and 10, baseline measures are repeated. Between visit 6-7, visit 7-8, visit 8-9 and visit 9-10, a phone call is planned to assess general psychopathology, adverse events and concomitant medication. The treatment duration is one year for each participant; with a safety follow up 4 weeks after the end of the trial. All participants are treated with XT open label.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
12a. Have history or high risk of urinary retention. 12b. All grades of hepatic impairment (mild [ Class A], moderate [Child-Pugh Class B], and severe [Child-Pugh Class C]).
12c. Elevations in hepatic transaminases at screening ≥ 2× for and AST and/or > 2 × ULN, unless in the context of Gilbert's syndrome.
12d. Have a history or high risk for narrow-angle glaucoma. 12e. Active biliary disease (e.g., symptomatic gallstones). Participants with other biliary histories are eligible and should be discussed with the sponsor.
12f. Participants with a history of bladder stones . 12g. Participants with a history of recurrent urinary tract infections. 12h. For all male participants, serum prostate-specific antigen >10 ng/mL at screening.
12i. For male participants ≥ 45 years of age, an IPSS score of 5 (i.e, "almost always") on items 1, 3, 5, or 6, and/or for male participants ≥ 45 years of age, an IPSS score ≥ 9 for the sum of items 1, 3, 5, and 6.
12j. An of \< 60 mL/min (which indicates renal dysfunction). 12k. History of unstable hypertension or tachycardia as evidenced by a blood pressure of ≥ 160/100 mmHg at screening and/or a heart rate of ≥ 110 bpm at screening.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Xanomeline/trospium that is provided to all participants
Drug: Xanomeline/trospium
Drug pages: XanomelineStudies of XanomelineXanomeline pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TrospiumStudies of TrospiumTrospium pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Participants will receive oral xanomeline/trospium during the trial (target dose 125/30 BID).
Also known as: KarXT/Cobenfy
Change in cognitive performance after 24 weeks of treatment, relative to baseline.
The within-participant change in the Brief Assessment of Cognition in Schizophrenia composite cognitive score from baseline to follow-up after 24 weeks. Higher score means better cognition. There is no max score, as the tests have different scoring methods (number correct, reaction time).
Time frame: 24 weeks
Change in negative symptoms after 24 weeks of treatment, relative to baseline.
The within-participant change in the Positive And Negative Syndrome Scale (PANSS) negative subscale from baseline to follow-up after 24 weeks. A higher score means more schizophrenia-related symptoms. The maximum score is 49.
Time frame: 24 weeks
Change in Functional Skills assessment and training (FUNSAT) scores for ATM banking, ticket kiosk, and medication management after 12, 24 and 52 weeks of treatment, relative to baseline.
The within-participant change in the Functional Skills assessment and training (FUNSAT) scores for ATM banking, ticket kiosk and medication management from baseline to follow-up after 12, 24 and 52 weeks. Higher reaction time scores means worse functioning (without maximum), higher number correct means better functioning
Time frame: 12, 24 and 52 weeks
Change in Subjective Scale to Investigate Cognition in Schizophrenia (SSTICS) between baseline and week 24
The within-participant change in Subjective Scale to Investigate Cognition in Schizophrenia (SSTICS) between baseline and week 24. A higher score means better subjective and social cognition.
Time frame: 24 weeks
Change in Subjective Scale to Investigate Social Cognition Scale scores (MRMET) between baseline and week 24
The within-participant change in Social Cognition Scale scores (MRMET) between baseline and week 24. A higher score means better subjective and social cognition.
Time frame: 24 weeks
Change in Brief Assessment of Cognition in Schizophrenia (BACS) scores between baseline to week 12 and week 52.
The within-participant change in Brief Assessment of Cognition in Schizophrenia (BACS) scores between baseline to week 12 and week 52. Higher score means better cognition.There is no max score, as the tests have different scoring methods (number correct, reaction time).
Time frame: Week 12 and 52
Change in the Positive And Negative Syndrome Scale (PANSS) Negative Subscale Factor from baseline to week 12 and week 52
Within-participant change in the Positive And Negative Syndrome Scale (PANSS) Negative Subscale Factor from baseline to week 12 and week 52. A higher score means more schizophrenia-related symptoms. The maximum score is 49.
Time frame: Week 12 and 52
Change in the Brief Negative Symptom Scale (BNSS) and Self-report of Negative Symptoms (SNS) scores from baseline to week 24 and week 52.
Within-participant change in the Brief Negative Symptom Scale (BNSS) and Self-report of Negative Symptoms (SNS) scores from baseline to week 24 and week 52. A higher score on BNSS means more negative symptoms. The maximum score is 78. A higher score on SNS means more negative symptoms. The maximum score is 40.
Time frame: week 24 and 52
Change in the Positive And Negative Syndrome Scale (PANSS) Total and Positive Subscale scores from baseline to week 12; week 24 and week 52.
Within-participant change in the Positive And Negative Syndrome Scale (PANSS)Total and Positive Subscale scores from baseline to week 12; week 24 and week 52. A higher score means more schizophrenia-related symptoms. The PANSS total score has a maximum of 210, while the positive scale has a maximum of 49.
Time frame: Week 12, 24 and 52
Change in safety assessments from baseline to week 4; week 12; week 24 and week 52
Within-participant change in safety assessments from baseline to week 4; week 12; week 24 and week 52. This is defined as the occurence of AEs during the study. The is no minimum or maximum.
Time frame: week 4, 12, 24 and 52
Change in the physical examination (blood pressure (systolic/diastolic))
Within-participant change in the physical examination in the blood pressure (systolic/diastolic)) from baseline to week 12; week 24 and week 52.
Time frame: week 12, 24 and 52
Change in the physical examination (heart rate)
Within-participant change in the physical examination in the heart rate from baseline to week 12; week 24 and week 52.
Time frame: week 12, 24 and 52
Change in the physical examination( weight)
Within-participant change in the physical examination in the weight from baseline to week 12; week 24 and week 52.
Time frame: week 12, 24 and 52
Change in the physical examination (examination organ systems)
Within-participant change in the physical examination in the examination organ systems from baseline to week 12; week 24 and week 52.
Time frame: week 12, 24 and 52
Change in the physical examination(blood pressure, heart, rate, weight, examination organ systems)
Within-participant change in the physical examination (blood pressure, heart, rate, weight, examination organ systems) from baseline to week 12; week 24 and week 52.
Time frame: week 12, 24 and 52
Change in the Simpson Angus Scale (SAS) from baseline to week 12; week 24 and week 52.
Within-participant change in the Simpson Angus Scale (SAS) from baseline to week 12; week 24 and week 52. Higher scores on the SAS (max 40), means that the participants has more adverse events
Time frame: week 12, 24 and 52
Change in the Barnes Akathisia Rating Scale (BARS) from baseline to week 12; week 24 and week 52.
Within-participant change in the Barnes Akathisia Rating Scale (BARS) from baseline to week 12; week 24 and week 52. Higher scores on the BARS (max 14) mean more adverse events.
Time frame: week 12, 24 and 52
Change in the UKU Side Effect Rating Scale from baseline to week 12; week 24 and week 52.
Within-participant change in the UKU Side Effect Rating Scale from baseline to week 12; week 24 and week 52. Higher scores on the UKU (max 144) mean more adverse events.
Time frame: week 12, 24 and 52
Change in the ASSIST from baseline to week 12; week 24 and week 52.
Within-participant change in the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) from baseline to week 12; week 24 and week 52. H More items ticked on the ASSIST means that the participants has more addictions.
Time frame: week 12, 24 and 52
Incidence of treatment emergent adverse events (TEAE) defined as incidence of AEs observed from started of treatment initiation until the end of safety follow-up visit.
Incidence of treatment emergent adverse events (TEAE) defined as incidence of AEs observed from started of treatment initiation until the end of safety follow-up visit, will also be summarized by system organ class and preferred term (MedDRA). Serious TEAEs and TEAEs leading to study treatment discontinuation will also be summarized by system organ class and preferred term..
Time frame: Week 4, 12, 24, 52
Change in the Calgary Depression Scale for Schizophrenia (CDSS) total score from baseline to week 24 and week 52.
Within-participant Change in the Calgary Depression Scale for Schizophrenia (CDSS) total scores from baseline to week 24 and week 52. Higher scores means more depressive symptoms. The maximum score is 27.
Time frame: week 24 and 52
Change in the Clinical Global Impression-Severity/Improvement and Patient Glocal Impression-Severity/Improvement scores from baseline to week 12; week 24 and week 52.
Within-participant Change in the CGI-S/I and PGI-S/I scores from baseline to week 12; week 24 and week 52. Higher scores mean more symptom servity and less improvement. there are 4 questions in total. For the 2 S=severity questions, higher scores (max score: 7) means higher symptoms severity. For the 1 I=improvement questions, higher scores (max score: 7) mean less improvement
Time frame: week 12, 24 and 52
Change in the Personal and Social Performance Scale (PSP) total and subscale scores from baseline to week 24 and week 52
Within-participant change in the Personal and Social Performance Scale (PSP) total and subscale scores from baseline to week 24 and week 52. A higher total score means better performance (max score: 100). A lower score on the subquestions means less problems in functioning (max score: 24).
Time frame: week 24 and 52
Change in the Manchester Short Assessment of Quality of Life (MANSA) total score from baseline to week 24 and week 52.
Within-participant change in the Manchester Short Assessment of Quality of Life (MANSA)total score from baseline to week 24 and week 52. A higher score means better quality of life ans satisfaction. The maximum score is 112.
Time frame: week 24 and 52
Change in speech characteristics from baseline to week 24 and week 52
Within-participant change in speech characteristics from baseline to week 24 and week 52. This is analysed via speech NLP pipelines in 2 recordings of each participant that consented.
Time frame: week 24 and 52
Plan to share: Yes — Our Publication Policy is as follows: researchers can submit a request to receive the data. The Study Management Team will review and approve when appropriate. After having put into place the Data Transfer Agreement (plus Standard Contractual Clauses if receiving party is based outside the EU), the data can be shared through a secure, encrypted data sharing platform.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: To be determined
Access criteria: See publication policy described above.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.
How these figures are worked out, and which studies are left out of them.
Ethical committee in Europe did not provide approval
Ethical committee in Europe did not provide approval
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Xanomeline · Trospium